Cortical bone density by quantitative computed tomography mirrors disorders of bone structure in bone biopsy of non-dialysis CKD patients

Bittencourt, Amandha L.; Canziani, María Eugênia Fernandes; Costa, Libera Maria Dalla; Rochitte, Carlos Eduardo; Carvalho, Aluízio Barbosa de

doi:10.1016/j.bonr.2022.101166

Cited by 2 publications

(1 citation statement)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Peripheral quantitative computed tomography (pQCT) and its high-resolution derivate (HRpQCT) are low-radiation and low-cost imaging techniques [ 95 ] which are extremely useful for the evaluation of trabecular and cortical bone volumetric density [ 13 ]. pQCT accurately assesses bone volume and quality, showing a strong correlation with histologic exams [ 87 , 96 , 97 ]. HRpQCT provides greater resolution and direct quantification of cortical geometry and porosity, thickness, and trabecular parameters [ 98 ].…”

Section: Renal Osteodystrophy Osteoporosis and Bone Dysregulationmentioning

confidence: 99%

Chronic Kidney Disease with Mineral Bone Disorder and Vascular Calcification: An Overview

Izzo,

Secondulfo,

Bilancio

et al. 2024

Life

View full text Add to dashboard Cite

Chronic kidney disease (CKD) is a global health issue with a rising prevalence, affecting 697.5 million people worldwide. It imposes a substantial burden, contributing to 35.8 million disability-adjusted life years (DALYs) and 1.2 million deaths in 2017. The mortality rate for CKD has increased by 41.5% between 1990 and 2017, positioning it as a significant cause of global mortality. CKD is associated with diverse health complications, impacting cardiovascular, neurological, nutritional, and endocrine aspects. One prominent complication is CKD–mineral and bone disorder (MBD), a complex condition involving dysregulation of bone turnover, mineralization, and strength, accompanied by soft tissue and vascular calcification. Alterations in mineral metabolism, including calcium, phosphate, parathyroid hormone (PTH), vitamin D, fibroblast growth factor-23 (FGF-23), and Klotho, play pivotal roles in CKD-MBD. These disturbances, observed early in CKD, contribute to the progression of bone disorders and renal osteodystrophy (ROD). Vascular calcification (VC) is a key component of CKD-MBD, accelerated by CKD. The pathophysiology involves complex processes in vascular smooth muscle cells and the formation of calciprotein particles (CPP). VC is closely linked to cardiovascular events and mortality, emphasizing its prognostic significance. Various serum markers and imaging techniques, including lateral plain X-ray, Kauppila Score, Adragao Score, and pulse wave velocity, aid in VC detection. Additionally, pQCT provides valuable information on arterial calcifications, offering an advantage over traditional scoring systems. CKD poses a substantial global health burden, and its complications, including CKD-MBD and VC, significantly contribute to morbidity and mortality. Understanding the intricate relationships between mineral metabolism, bone disorders, and vascular calcification is crucial for effective diagnosis and therapeutic interventions.

show abstract

Section: Renal Osteodystrophy Osteoporosis and Bone Dysregulationmentioning

confidence: 99%

Chronic Kidney Disease with Mineral Bone Disorder and Vascular Calcification: An Overview

Izzo,

Secondulfo,

Bilancio

et al. 2024

Life

View full text Add to dashboard Cite

show abstract

Current and Emerging Markers and Tools Used in the Diagnosis and Management of Chronic Kidney Disease–Mineral and Bone Disorder in Non-Dialysis Adult Patients

Fusaro,

Pereira,

Bover

2023

JCM

View full text Add to dashboard Cite

Chronic kidney disease (CKD) is a significant public health concern associated with significant morbidity and has become one of the foremost global causes of death in recent years. A frequent comorbidity of CKD is secondary hyperparathyroidism (SHPT), exemplified by high serum parathyroid hormone (PTH) levels. The mineral metabolism disturbances resulting from CKD and progression to SHPT are currently considered part of the definition of chronic kidney disease–mineral and bone disorder (CKD-MBD). However, CKD-MBD does not only include abnormalities in laboratory-measured parameters; it is a complex condition characterized by dysregulation of bone turnover, mineralization, growth and strength, accompanied by vascular or another soft-tissue calcification. Together, this increases the risk of bone fractures, cardiovascular disease, and overall mortality in CKD-MBD patients. Monitoring serum markers is essential in diagnosing SHPT and CKD-MBD, and there are several recognized indicators for prognosis, optimal clinical management and treatment response in late-stage kidney disease patients receiving dialysis. However, far fewer markers have been established for patients with non-dialysis CKD. This review provides an overview of current and emerging markers and tools used in the diagnosis and management of CKD-MBD in non-dialysis adult patients.

show abstract

Cortical bone density by quantitative computed tomography mirrors disorders of bone structure in bone biopsy of non-dialysis CKD patients

Cited by 2 publications

References 34 publications

Chronic Kidney Disease with Mineral Bone Disorder and Vascular Calcification: An Overview

Chronic Kidney Disease with Mineral Bone Disorder and Vascular Calcification: An Overview

Current and Emerging Markers and Tools Used in the Diagnosis and Management of Chronic Kidney Disease–Mineral and Bone Disorder in Non-Dialysis Adult Patients

Contact Info

Product

Resources

About